Synthesis method of dapagliflozin

Through the synthetic method without using butyl lithium, carbon nanofibers prepared from gallium acetylacetonate, amidinourea phosphate and chitosan are used to condensate and demethoxy reactions in the prior art, the operation difficulties and equipment requirements are solved in the prior art. Strict problems have achieved high yield and high purity preparation of dapagliflozin intermediate A.

CN118908926APending Publication Date: 2024-11-08ANHUI HAIKANG PHARMA
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410996350.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing dapagliflozin synthesis method requires the use of butyl lithium and low temperature (-78°C) reaction. The equipment and operating conditions are strictly required, and there are problems of operational difficulties and high cost.

Method used

By using a synthetic method without butyl lithium, 4-(5-bromo-2-chlorobenzyl)phenylether and 2,3,4,6-tetra-0-trimethylsilyl-D-gluconic acid The lactone condenses under the action of a catalyst, then reacts with methanesulfonic acid, and undergoes demethoxy reaction under the action of zinc chloride and triethylsilane to obtain dapagliflozin. The catalyst is prepared from gallium acetylacetonate, amidinourea phosphate and chitosan by calcination and impregnation to form nitrogen, phosphorus, and gallium doped modified carbon nanofibers to facilitate the reaction.

Benefits of technology

The yield of dapagliflozin intermediate A is achieved above 90% and high purity, which simplifies operating conditions, reduces equipment requirements, and improves the catalytic capacity of the catalyst.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908926A_ABST
    Figure CN118908926A_ABST
Patent Text Reader

Abstract

The invention discloses a dapagliflozin synthesis method, which comprises: synthesizing an intermediate A, carrying out condensation on 4-(5-bromo-2-chlorobenzyl) phenetole and 2, 3, 4, 6-tetra-0-trimethylsilyl-D-glucolactone under the action of a catalyst, and carrying out a reaction with methanesulfonic acid to obtain the intermediate A; synthesis of dapagliflozin: the intermediate A is subjected to a demethoxylation reaction under the action of zinc chloride and triethyl silane, and dapagliflozin is obtained. Compared with the prior art, the method has the beneficial effects that the yield of the dapagliflozin key intermediate A obtained by adopting the catalyst prepared by the method is 90% or above, and the dapagliflozin key intermediate A has higher purity and can be directly used for next-step preparation of dapagliflozin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of chemical engineering, and in particular to a method for synthesizing dapagliflozin. Background Art

[0002] Dapagliflozin, whose chemical name is (2S,3R,4R,5S,6R)-2-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol, was jointly developed by Bristol-Myers Squibb and AstraZeneca. It is the first sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes.

[0003] In the prior art, patent CN101628905A discloses a method for synthesizing dapagliflozin, in which 5-bromo-2-chloro-4'-ethoxydiphenylmethane reacts with butyl lithium at a low temperature of -78°C to generate a phenyl lithium intermediate; then, a condensation reaction occurs with gluconolactone at -70°C, and the reaction is quenched in a trifluoromethanesulfonic acid and methanol solution, and finally, triethylsilane and boron trifluoride etherate are used to remove the methoxy group to obtain dapagliflozin. This route uses butyl lithium and requires low temperature (-78°C) nitrogen protection operation, which places strict requirements on equipment and other conditions. Summary of the invention

[0004] In order to solve the problems mentioned in the above background technology, the present invention provides a method for synthesizing dapagliflozin, which does not require the use of butyl lithium and does not require low temperature (-78° C.) reaction.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions: A method for synthesizing dapagliflozin comprises the following steps: Synthesis of Intermediate A 4-(5-bromo-2-chlorobenzyl)phenethyl ether and 2,3,4,6-tetra-0-trimethylsilyl-D-gluconolactone are condensed under the action of a catalyst and then reacted with methanesulfonic acid to obtain intermediate A; Synthesis of dapagliflozin Intermediate A undergoes a demethoxylation reaction under the action of zinc chloride and triethylsilane to obtain dapagliflozin.

[0006] Preferably, the preparation method of the catalyst is as follows: Under nitrogen protection, gallium acetylacetonate, guanyl urea phosphate and chitosan are mixed evenly and calcined to obtain nitrogen, phosphorus and gallium doped modified carbon nanofibers. The modified carbon nanofibers are added to an aqueous solution of ferric chloride, and then an aqueous solution of hydrogen peroxide is added, impregnated, filtered, washed with water, and dried to obtain a catalyst.

[0007] Preferably, the addition amount of gallium acetylacetonate is 6‰-16‰ of the mass of chitosan.

[0008] Preferably, the added amount of the guanyl phosphate urea is 2‰-10‰ of the mass of chitosan.

[0009] Preferably, the calcination conditions are: 600° C., 3 h.

[0010] Preferably, the concentration of the ferric chloride aqueous solution is 0.05-0.15 mol / L.

[0011] Preferably, the mass fraction of the aqueous hydrogen peroxide solution is 5%-15%.

[0012] Compared with the prior art, the present invention has the following beneficial effects: 1. The yield of the key intermediate A of dapagliflozin obtained by using the catalyst prepared by the present invention is above 90%, and has a high purity, and can be directly used for the preparation of dapagliflozin in the next step.

[0013] 2. The present invention obtains nitrogen-, phosphorus- and gallium-doped carbon nanofibers by calcining gallium acetylacetonate, guanyl urea phosphate and chitosan. The presence of nitrogen and phosphorus can not only serve as coordination sites to make gallium uniformly and stably dispersed on the carbon nanofibers, but also can adjust the electron density of the carbon nanofibers, increase the active sites of gallium through electron transfer, and then further impregnate the carbon nanofibers in ferric chloride and hydrogen peroxide to form a bimetallic catalytic system. The electron transfer between the bimetals and the coordination synergy of nitrogen and phosphorus jointly enhance the catalytic ability of the catalyst. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is the reaction equation for dapagliflozin. DETAILED DESCRIPTION

[0015] Unless otherwise specified, the raw materials and reagents used in the present invention are commercially available or can be prepared by known methods.

[0016] Preparation Example 1 Under nitrogen protection, 10 g of gallium acetylacetonate, 6 g of guanyl phosphate urea and 1000 g of chitosan were mixed evenly and calcined at 600 ° C for 3 h to obtain nitrogen-, phosphorus- and gallium-doped carbon nanofibers. The modified carbon nanofibers were added to a 0.1 mol / L ferric chloride aqueous solution (2.5 L), and then a 10% mass fraction hydrogen peroxide aqueous solution (2.5 L) was added, immersed for 10 h, filtered, washed with water, and dried to obtain a catalyst.

[0017] Preparation Example 2 The difference between this preparation example and preparation example 1 is that: Mix 10 g of gallium acetylacetonate, 2 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0018] Preparation Example 3 The difference between this preparation example and preparation example 1 is that: Mix 10 g of gallium acetylacetonate, 10 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0019] Preparation Example 4 The difference between this preparation example and preparation example 1 is that: Mix 6 g of gallium acetylacetonate, 6 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0020] Preparation Example 5 The difference between this preparation example and preparation example 1 is that: Mix 16 g of gallium acetylacetonate, 6 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0021] Preparation Example 6 The difference between this preparation example and preparation example 1 is that: Mix 0 g of gallium acetylacetonate, 6 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0022] Preparation Example 7 The difference between this preparation example and preparation example 1 is that: Mix 10 g of gallium acetylacetonate, 0 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1.

[0023] Preparation Example 8 The difference between this preparation example and preparation example 1 is that: Mix 20 g of gallium acetylacetonate, 15 g of guanyl urea phosphate and 1000 g of chitosan evenly; The rest is exactly the same as Preparation Example 1. Example 1

[0024] A method for synthesizing dapagliflozin comprises the following steps: Synthesis of Intermediate A Under nitrogen protection, 325 g of 4-(5-bromo-2-chlorobenzyl)phenethyl ether, 0.5 kg of tetrahydrofuran, and 1.5 kg of toluene were added to the reactor, stirred and mixed evenly, 10 g of catalyst (Preparation Example 1) was added, and a toluene solution of 2,3,4,6-tetra-0-trimethylsilyl-D-gluconolactone (530 g, 2 kg) was added dropwise to the reactor at 0°C. After the addition was completed, the reaction was continued to stir for 1 h, and 1 kg of methanol solution of methanesulfonic acid (0.45 kg, 0.55 kg) was added. The reaction was stirred at 0°C for 4 h, and the sample was taken for detection. The temperature was raised to 30°C and stirred for 5 h. The pH was adjusted to 7-8 with a 3 mol / L aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate and repeated 3 times. The organic phases were combined, and the organic phases were washed with a saturated aqueous sodium chloride solution until neutral, dried with anhydrous sodium sulfate, filtered, concentrated, washed with ice methanol, and dried in vacuo to obtain intermediate A. The yield of intermediate A was 93.5% and the purity was 99.31%. Synthesis of dapagliflozin Add 300 g of intermediate A, 500 g of dichloromethane and 500 g of acetonitrile to a reactor, stir and mix evenly, add 20 g of zinc chloride at -5°C, stir for 30 min, add 100 g of triethylsilane dropwise, and after the addition is completed, heat to 20°C and react for 2 h, cool to -5°C, add saturated sodium bicarbonate solution dropwise to adjust the pH to 6-7, extract with ethyl acetate, repeat 3 times, combine the organic phases, wash the organic phases with saturated sodium chloride solution until neutral, add anhydrous sodium sulfate to dry, filter, concentrate, wash with ice methanol, and vacuum dry to obtain dapagliflozin, with a dapagliflozin yield of 78.3% and a purity of 99.56%.

[0025] Embodiment 2-9 The implementation conditions were the same as those in Example 1, except that catalysts obtained from different preparation examples were used. The results are shown in Table 1.

[0026] Table 1

[0027] According to Table 1, it can be seen from Examples 1-5 that the yield of the key intermediate A of dapagliflozin catalyzed by the catalyst prepared by the present invention is above 90%, and has a high purity, and can be directly used in the next step of preparing dapagliflozin.

[0028] It can be seen from Examples 6 and 7 that without adding gallium acetylacetonate (Example 6), the yield of intermediate A is only 25.7%, and the purity is only 81.63%. Without adding guanyl phosphate urea (Example 7), the yield of intermediate A is only 18.9%, and the purity is only 76.36%. As a result, whether gallium acetylacetonate or guanyl phosphate urea is lacking, the catalytic effect of the catalyst is significantly reduced, and the simultaneous use of the two produces a significant synergistic enhancement effect.

[0029] It can be seen from Example 8 that when more gallium acetylacetonate and guanyl urea phosphate are added (Example 8), the yield of intermediate A is only 56.6%, and the purity is only 85.32%. When excessive gallium acetylacetonate and guanyl urea phosphate are added, the catalytic effect is significantly reduced.

[0030] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for synthesizing dapagliflozin, characterized in that: The steps include: Synthesis of Intermediate A 4-(5-bromo-2-chlorobenzyl)phenethyl ether and 2,3,4,6-tetra-0-trimethylsilyl-D-gluconolactone are condensed under the action of a catalyst and then reacted with methanesulfonic acid to obtain intermediate A; Synthesis of dapagliflozin Intermediate A undergoes a demethoxylation reaction under the action of zinc chloride and triethylsilane to obtain dapagliflozin.

2. The method for synthesizing dapagliflozin according to claim 1, characterized in that: The preparation method of the catalyst is as follows: Under nitrogen protection, gallium acetylacetonate, guanyl urea phosphate and chitosan are mixed evenly and calcined to obtain nitrogen, phosphorus and gallium doped modified carbon nanofibers. The modified carbon nanofibers are added to an aqueous solution of ferric chloride, and then an aqueous solution of hydrogen peroxide is added, impregnated, filtered, washed with water, and dried to obtain a catalyst.

3. The method for synthesizing dapagliflozin according to claim 2, characterized in that: The added amount of gallium acetylacetonate is 6‰-16‰ of the mass of chitosan.

4. The method for synthesizing dapagliflozin according to claim 2, characterized in that: The added amount of the guanyl phosphate urea is 2‰-10‰ of the mass of chitosan.

5. The method for synthesizing dapagliflozin according to claim 2, characterized in that: The calcination conditions are: 600° C., 3 h.

6. The method for synthesizing dapagliflozin according to claim 2, characterized in that: The concentration of the ferric chloride aqueous solution is 0.05-0.15 mol / L.

7. The method for synthesizing dapagliflozin according to claim 2, characterized in that: The mass fraction of the aqueous hydrogen peroxide solution is 5%-15%.

Citation Information

Patent Citations

  • C-aryl glucoside sglt2 inhibitors and method

    CN101628905A

  • Preparation methods of SGLT-2 diabetes inhibitors and intermediates thereof

    CN107163092A

  • Dapagliflozin preparation method

    CN107540648A

  • Preparation method for hypoglycemic drugdapagliflozin

    CN108084130A